Dolby Laboratories, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dolby Laboratories, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 24, 2021 | $1.28B | Nov 17, 2021 |
| FY2020 | Sep 25, 2020 | $271.19M | Nov 16, 2020 |
| FY2020 | Jun 26, 2020 | $246.91M | Nov 16, 2020 |
| FY2020 | Mar 27, 2020 | $351.82M | Nov 16, 2020 |
| FY2020 | Dec 27, 2019 | $291.88M | Nov 16, 2020 |
| FY2020 | Sep 27, 2019 | $298.83M | Nov 16, 2020 |
| FY2020 | Jun 28, 2019 | $302.16M | Nov 16, 2020 |
| FY2020 | Mar 29, 2019 | $338.26M | Nov 16, 2020 |
| FY2020 | Dec 28, 2018 | $302.38M | Nov 16, 2020 |
| FY2018 | Sep 28, 2018 | $265.33M | Nov 15, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $1.35B | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $1.27B | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $1.30B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $1.25B | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $1.28B | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $1.16B | Nov 18, 2022 |
| FY2019 | Sep 27, 2019 | $298.83M | Nov 25, 2019 |
| FY2019 | Jun 28, 2019 | $302.16M | Nov 25, 2019 |
| FY2019 | Mar 29, 2019 | $338.26M | Nov 25, 2019 |
| FY2019 | Dec 28, 2018 | $302.38M | Nov 25, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $1.19B | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $1.13B | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $1.15B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $1.11B | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $1.15B | Nov 17, 2023 |
| FY2020 | Sep 25, 2020 | $228.73M | Nov 16, 2020 |
| FY2020 | Jun 26, 2020 | $217.02M | Nov 16, 2020 |
| FY2020 | Mar 27, 2020 | $314.99M | Nov 16, 2020 |
| FY2020 | Dec 27, 2019 | $254.56M | Nov 16, 2020 |
| FY2020 | Sep 27, 2019 | $252.87M | Nov 16, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $255.02M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $261.83M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $200.66M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $184.09M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $310.23M | Nov 17, 2023 |
| FY2020 | Sep 25, 2020 | $26.83M | Nov 16, 2020 |
| FY2020 | Jun 26, 2020 | $67.29M | Nov 16, 2020 |
| FY2020 | Mar 27, 2020 | $88.50M | Nov 16, 2020 |
| FY2020 | Dec 27, 2019 | $48.75M | Nov 16, 2020 |
| FY2020 | Sep 27, 2019 | $43.92M | Nov 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $264.96M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $258.33M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $215.75M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $206.61M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $344.39M | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $218.74M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $257.08M | Nov 17, 2021 |
| FY2020 | Sep 28, 2018 | $183.51M | Nov 16, 2020 |
| FY2019 | Sep 29, 2017 | $247.13M | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | $231.80M | Nov 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $261.79M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $263.66M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $271.52M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $261.17M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $253.64M | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $239.05M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $237.87M | Nov 17, 2021 |
| FY2020 | Sep 28, 2018 | $236.79M | Nov 16, 2020 |
| FY2019 | Sep 29, 2017 | $233.31M | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | $219.61M | Nov 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $472.20M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $327.25M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $367.08M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $318.58M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $447.75M | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $343.85M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $327.67M | Nov 17, 2021 |
| FY2020 | Sep 28, 2018 | $352.20M | Nov 16, 2020 |
| FY2019 | Sep 29, 2017 | $377.79M | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | $360.06M | Nov 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $36.35M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $30.01M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $30.34M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $47.93M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $54.45M | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $66.35M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $96.28M | Nov 17, 2021 |
| FY2020 | Sep 28, 2018 | $72.81M | Nov 16, 2020 |
| FY2019 | Sep 29, 2017 | $99.62M | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | $100.76M | Nov 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $3.23B | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $3.11B | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $2.98B | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $2.69B | Nov 17, 2023 |
| FY2022 | Sep 24, 2021 | $3.11B | Nov 18, 2022 |
| FY2021 | Sep 25, 2020 | $2.92B | Nov 17, 2021 |
| FY2020 | Sep 27, 2019 | $2.82B | Nov 16, 2020 |
| FY2019 | Sep 28, 2018 | $2.87B | Nov 25, 2019 |
| FY2018 | Sep 29, 2017 | $2.53B | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $2.31B | Nov 16, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $595.81M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $623.04M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $607.58M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $438.53M | Nov 17, 2023 |
| FY2022 | Sep 24, 2021 | $501.46M | Nov 18, 2022 |
| FY2021 | Sep 25, 2020 | $478.92M | Nov 17, 2021 |
| FY2020 | Sep 27, 2019 | $508.72M | Nov 16, 2020 |
| FY2019 | Sep 28, 2018 | $494.88M | Nov 25, 2019 |
| FY2018 | Sep 29, 2017 | $389.71M | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $331.37M | Nov 16, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $2.62B | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $2.48B | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $2.36B | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $2.25B | Nov 17, 2023 |
| FY2022 | Sep 24, 2021 | $2.60B | Nov 18, 2022 |
| FY2021 | Sep 25, 2020 | $2.43B | Nov 17, 2021 |
| FY2020 | Sep 27, 2019 | $2.31B | Nov 16, 2020 |
| FY2019 | Sep 28, 2018 | $2.36B | Nov 25, 2019 |
| FY2018 | Sep 29, 2017 | $2.14B | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $1.97B | Nov 16, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $529.90M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $533.21M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $408.41M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $365.15M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $340.69M | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $336.95M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $334.83M | Nov 17, 2021 |
| FY2020 | Sep 28, 2018 | $327.98M | Nov 16, 2020 |
| FY2019 | Sep 29, 2017 | $311.09M | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | $309.62M | Nov 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $2.63B | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $2.50B | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $2.39B | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $2.30B | Nov 17, 2023 |
| FY2022 | Sep 24, 2021 | $2.61B | Nov 18, 2022 |
| FY2021 | Sep 25, 2020 | $2.44B | Nov 17, 2021 |
| FY2020 | Sep 27, 2019 | $2.33B | Nov 16, 2020 |
| FY2019 | Sep 28, 2018 | $2.31B | Nov 25, 2019 |
| FY2018 | Sep 29, 2017 | $2.08B | Nov 15, 2018 |
| FY2017 | Sep 30, 2016 | $1.94B | Nov 16, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $701.89M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $482.05M | Nov 18, 2025 |
| FY2024 | Sep 29, 2023 | $745.36M | Nov 19, 2024 |
| FY2023 | Sep 30, 2022 | $620.13M | Nov 17, 2023 |
| FY2022 | Sep 24, 2021 | $1.23B | Nov 18, 2022 |
| FY2021 | Sep 25, 2020 | $1.07B | Nov 17, 2021 |
| FY2020 | Sep 27, 2019 | $797.21M | Nov 16, 2020 |
| FY2019 | Sep 28, 2018 | $918.06M | Nov 25, 2019 |
| FY2019 | Sep 29, 2017 | $634.37M | Nov 25, 2019 |
| FY2019 | Sep 30, 2016 | $519.76M | Nov 25, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | 2 | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | 2 | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | 2 | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | 1 | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | 3 | Nov 17, 2023 |
| FY2020 | Sep 25, 2020 | 0 | Nov 16, 2020 |
| FY2020 | Jun 26, 2020 | 0 | Nov 16, 2020 |
| FY2020 | Mar 27, 2020 | 0 | Nov 16, 2020 |
| FY2020 | Dec 27, 2019 | 0 | Nov 16, 2020 |
| FY2020 | Sep 27, 2019 | 0 | Nov 16, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | 2 | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | 2 | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | 2 | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | 1 | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | 2 | Nov 17, 2023 |
| FY2020 | Sep 25, 2020 | 0 | Nov 16, 2020 |
| FY2020 | Jun 26, 2020 | 0 | Nov 16, 2020 |
| FY2020 | Mar 27, 2020 | 0 | Nov 16, 2020 |
| FY2020 | Dec 27, 2019 | 0 | Nov 16, 2020 |
| FY2020 | Sep 27, 2019 | 0 | Nov 16, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 26, 2025 | $126.60M | Nov 18, 2025 |
| FY2025 | Sep 27, 2024 | $114.58M | Nov 18, 2025 |
| FY2025 | Sep 29, 2023 | $103.41M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $100.07M | Nov 19, 2024 |
| FY2023 | Sep 24, 2021 | $89.17M | Nov 17, 2023 |
| FY2022 | Sep 25, 2020 | $88.58M | Nov 18, 2022 |
| FY2021 | Sep 27, 2019 | $77.50M | Nov 17, 2021 |
| FY2020 | Sep 28, 2018 | $66.16M | Nov 16, 2020 |